Le Lézard
Classified in: Science and technology, Business
Subjects: FNC, ACC, FVT

UPDATE: ChipMOS SUBMITS CAPITAL REDUCTION TO NASDAQ


HSINCHU, Taiwan, Oct. 12, 2018 /PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and NASDAQ: IMOS), an industry leading provider of outsourced semiconductor assembly and test services ("OSAT"), announced it has submitted a capital reduction form to NASDAQ, as notification of the following actions for the Company's American Depositary Shares ("ADRs"):

Questions regarding the Company's 2018 Capital Reduction Plan distribution may be directed to Thomas Wood ([email protected]) at +1.212.816.6530.

About ChipMOS TECHNOLOGIES INC.:

ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and NASDAQ: IMOS) (http://www.chipmos.com) is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS provide assembly and test services to a broad range of customers, including leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries.

Forward-Looking Statements

This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes,' 'expects,' 'anticipates,' 'projects,' 'intends,' 'should,' 'seeks,' 'estimates,' 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. Further information regarding these risks, uncertainties and other factors are included in the Company's most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") and in the Company's other filings with the SEC.

Contacts:

In Taiwan

Dr. G.S. Shen

ChipMOS TECHNOLOGIES INC.

+886-3-5668877

[email protected]

 

In the U.S.

David Pasquale

Global IR Partners

+1-914-337-8801

[email protected] 

SOURCE ChipMOS TECHNOLOGIES INC.


These press releases may also interest you

at 15:20
One of the main roles of the spleen is to help the body's immune system fight infections. The spleen does this through producing and regulating antibodies ? antibody production is negatively affected in various conditions, including sepsis and...

at 15:09
Radiance Technologies (Radiance) is pleased to announce the promotion of Mr. Seth Crochet to Vice President, General Counsel. In his new role, Mr. Crochet will continue to oversee all legal matters within and related to Radiance while serving as the...

at 15:00
DealerFire, a leader in automotive digital marketing, is revolutionizing how dealerships showcase their inventory and connect with customers online with its innovative Engine6 website platform. Engine6 empowers dealerships to create fully customized...

at 15:00
"Whether you have forgotten your Nokia phone's screen lock password or have it carrier-locked to a network, there are several foolproof ways to help unlock it," says Tenorshare. In this article, we will discuss how to unlock Nokia phone using...

at 14:50
BancTrust & Co. Investment Bank (BancTrust), the London-based Emerging Markets investment bank, is excited to announce a significant milestone in its growth journey. The company recently relocated its headquarters to a state-of-the-art building...

at 14:38
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: "A Milestone in Facilitating the Development of Safe and Effective Biosimilars," by Sarah Yim,...



News published on and distributed by: